Acute Lymphoid Leukemia Clinical Trial
Official title:
National Treatment Program With Sequential Chemotherapy and Blinatumomab to Improve Minimal Residual Disease Response and Survival in Philadelphia Chromosome-Negative B-Cell Precursor Adult Acute Lymphoblastic Leukemia
The present study aims at analyzing the response to treatment of adult patients homogeneously treated with supportive care, chemotherapy and blinatumomab.
Eligible patients with CD19+ Ph- BCP ALL (Philadelphia-negative B-cell precursor acute lymphoblastic leukemia) will receive homogeneous supportive care, chemotherapy and blinatumomab immunotherapy, and will be homogeneously analyzed for response at prefixed time points from induction day 1. For risk-oriented therapy, patients in complete remission (CR) will be stratified by risk class according to the diagnostic characteristics and MRD (minimal residual disease) study results during early consolidation. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05959720 -
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil
|
||
| Recruiting |
NCT02933333 -
G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor
|
Phase 4 | |
| Completed |
NCT02953730 -
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
|
Phase 4 | |
| Completed |
NCT02767388 -
Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
|
||
| Recruiting |
NCT03610438 -
Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Recruiting |
NCT05792007 -
Study of the Medullary Microenvironment in Acute Childhood Leukemia
|
N/A | |
| Completed |
NCT02294552 -
Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT
|
Phase 2 | |
| Completed |
NCT01461538 -
Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies
|
Phase 2 | |
| Recruiting |
NCT04167683 -
Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant
|
||
| Recruiting |
NCT05150561 -
Muscle Dysfunction in Patients With Haematological Diseases
|
||
| Active, not recruiting |
NCT04669210 -
PTCy and Ruxolitinib vs PTCy, Tacrolimus and MMF in MUD and Haploidentical HSCT
|
Phase 2 | |
| Recruiting |
NCT04013685 -
Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 1 | |
| Recruiting |
NCT02345915 -
Evaluation of Adverse Long-term Effects in Young Adult Survivors of Acute Leukemia
|
N/A | |
| Completed |
NCT01720264 -
Multicenter Phase II of CD26 Using Sitagliptin for Engraftment After UBC Transplant
|
Phase 2 | |
| Not yet recruiting |
NCT02413021 -
The Effect of Deferasirox on Response Rate of Acute Leukemia Patients Not Treated by Standard Chemotherapy Regimens
|
Phase 1 | |
| Active, not recruiting |
NCT04778579 -
Study of the Infusion of ARI-0001 Cells in Patients With CD19 + Acute Lymphoid Leukemia Resistant or Refractory to Therapy
|
Phase 2 | |
| Recruiting |
NCT03448393 -
CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
|
Phase 1 | |
| Completed |
NCT03833180 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)
|
Phase 1 | |
| Terminated |
NCT02435550 -
iCare for Cancer Patients
|
N/A | |
| Recruiting |
NCT05316701 -
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
|
Phase 3 |